Home > Journals > Minerva Obstetrics and Gynecology > Past Issues > Minerva Ginecologica 2010 October;62(5) > Minerva Ginecologica 2010 October;62(5):433-45

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

  GINECOLOGY UPDATE 

Minerva Ginecologica 2010 October;62(5):433-45

Copyright © 2010 EDIZIONI MINERVA MEDICA

language: English

Managemt of endometrial hyperplasia

Gültekin M. 1, Dogan N. U. 2, Aksan G. 3, Ozgul N. 1

1 Department of Cancer Control, Turkish Ministry of Health, Ankara, Turkey; 2 Zekai Tahir Burak Maternity Hospital,, Ankara, Turkey; 3 Baskent University Faculty of Medicine, Istanbul, Turkey


PDF


Endometrial hyperplasia is a commonly seen clinical entity. A great majority of patients present with abnormal uterine bleeding. Unopposed estrogen either from an endogenous or exogenous source is the most important etiologic factor. Etiologic evaluation and cause specific treatment is a must for these patients instead of direct biopsies and treatments. Clinical importance of this pathological entity is the underlying risk of carrying a concomitant genital cancer and the potential risk of progression to endometrial carcinoma during the follow-up. Despite to a great effort on research and a long history of the disease in the medical literature; we still do not have a practical and accurate system available to use during daily practice in order to differentiate the real precancerous lesions. Treatment of endometrial hyperplasia depends on the patient’s age, fertility desire and the type of present hyperplasia. Progestagens are still the most commonly used medical treatment modality in these patients. Response rates are higher in cases without atypia. In selected cases, hysterectomy may be performed as a definitive treatment modality. In this review article current management of the endometrial hyperplasia is summarized in the light of associated literature.

top of page